Although several HER2-targeting agents, including trastuzumab and its biosimilar compounds, such as samfenet and herzuma, are FDA-approved for HER2-overexpressing breast and gastric cancers, no such agents have been approved for HER2-overexpressing ovarian cancer [19,35,36]. This evidence concerns the gene ERBB2 and gastric cancer.